Value of peripheral blood albumin and fibrinogen levels in the prognostic evaluation of advanced non-small cell lung cancer

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-12-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.12.008

Lin Quan, Ling-Tong Xu, Wenping Chen

{"title":"Value of peripheral blood albumin and fibrinogen levels in the prognostic evaluation of advanced non-small cell lung cancer","authors":"Lin Quan, Ling-Tong Xu, Wenping Chen","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). \n \n \nMethods \nA total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. \n \n \nResults \nThe median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. \n \n \nConclusions \nIn patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. \n \n \nKey words: \nCacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"828-831"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). Methods A total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. Results The median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. Conclusions In patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. Key words: Cacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis

查看原文本刊更多论文

外周血白蛋白和纤维蛋白原水平在晚期非小细胞肺癌预后评价中的价值

目的探讨外周血白蛋白和纤维蛋白原水平对晚期非小细胞肺癌(NSCLC)的临床预后价值。方法对2010年5月至2015年9月南京医科大学附属脑科医院胸科区收治的158例晚期非小细胞肺癌患者进行回顾性分析。所有患者均接受全身化疗加或不加局部放疗。收集患者临床病理特征及外周血蛋白、纤维蛋白原检测结果，分析外周血蛋白、纤维蛋白原水平与预后的相关性。结果血清白蛋白和血浆纤维蛋白原中位值分别为40.8 g/L (27.6 ~ 46.9 g/L)和3.4 g (2.4 ~ 5.2 g/L)，血清白蛋白与纤维蛋白原比值(AFR)中位值为12.1(6.2 ~ 17.0)。血清白蛋白升高组(≥40 g/L)和血清白蛋白降低组(<40 g/L)的中位总生存期(OS)分别为17.0和9.0个月，血浆纤维蛋白原升高组(≥40 g/L)和血浆纤维蛋白原降低组(<40 g/L)的中位总生存期(OS)分别为9.0和17.0个月。AFR升高组(≥10)和AFR降低组(<10)的中位OS时间分别为17.0和8.0个月，两组间差异有统计学意义(均P < 0.01)。多因素分析显示，血清白蛋白水平(HR = 1.58, 95% CI 1.20 ~ 2.06, P = 0.003)、血浆纤维蛋白原水平(HR = 1.43, 95% CI 1.01 ~ 2.03, P = 0.046)和AFR (HR = 1.81, 95% CI 1.22 ~ 2.62, P = 0.001)是OS的独立预后因素。结论在晚期NSCLC患者中，较高的白蛋白水平和/或较低的纤维蛋白原水平与较好的临床预后相关。外周血白蛋白、纤维蛋白原水平和AFR是晚期非小细胞肺癌的独立预后因素。关键词:肺癌;非小细胞肺;白蛋白;纤维蛋白原;预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.